Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 17/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.67 |
| ▸ | RBP4 | P02753 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27195841 | 0.88 | RBP4 (0.62) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL3902326 | 0.87 | RBP4 (0.60) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1763753 | 0.86 | RBP4 (0.61) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1918275 | 0.85 | RBP4 (0.58) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL3912829 | 0.85 | RBP4 (0.58) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1809088 | 0.84 | RBP4 (0.57) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1763572 | 0.82 | RBP4 (0.67) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL22074046 | 0.81 | RBP4 (0.55) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1763854 | 0.81 | RBP4 (0.55) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 | |
| SCHEMBL1764080 | 0.81 | RBP4 (0.61) | SLC9A1ADRA1DSLC6A3HTR2ASLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2321274-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | SLC9A1 2/4885ADRA1D 1467/4885SLC6A3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.